Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cubist's revenues up by 46% in the first half

This article was originally published in Scrip

Executive Summary

CubistPharmaceuticals' revenues in the second quarter were $101.8 million, virtually all from the lipopeptide Gram-positive antibiotic Cubicin (daptomycin), whose sales were $101.4 million, up 46% on the same period last year. Total half-year revenues were $190 million. The company also markets the carbapenem antibiotic Merrem iv (meropenem), in the US, following an agreement with AstraZeneca concluded in February.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC031548

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel